Peptides for the treatment of COVID-19
Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.
1. A composition comprising an isolated peptide that inhibits the association between SARS-CoV-2 spike Si of a SARS-CoV-2 variant and Angiotensin Converting Enzyme-2 (ACE-2) without inhibiting the activity of ACE-2, wherein the isolated peptide consists of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 9.
2. The composition according to claim 1 , wherein the SARS-CoV-2 variant comprises B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta) or B.1.1.529 (Omicron).
3. The composition according to claim 2 , wherein the peptide consists of SEQ ID NO: 5.
4. The composition according to claim 2 , wherein the peptide consists of SEQ ID NO: 6.
5. The composition according to claim 2 , wherein the peptide consists of SEQ ID NO: 7.
6. The composition according to claim 2 , wherein the peptide consists of SEQ ID NO: 9.
7. The composition according to claim 2 , wherein the peptide consists of SEQ ID NO: 3.
8. The composition according to claim 2 , wherein the peptide consists of SEQ ID NO: 4.
9. The composition according to claim 2 , comprising two or more isolated peptides selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 9.
10. The composition according to claim 2 , wherein the composition further comprises a cell penetrating peptide of SEQ ID NO: 13 joined to the N-terminus or the C-terminus of the isolated peptide.
11. A method of alleviating the symptoms associated with COVID-19, the method comprising administering a first agent to a subject in need thereof, the first agent comprising an isolated peptide that inhibits the association between SARS-CoV-2 spike 51 of a SARS-CoV-2 variant and Angiotensin Converting Enzyme-2 (ACE-2) without inhibiting the activity of ACE-2, wherein the first agent comprises an isolated peptide selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO:7, and SEQ ID NO: 9.
12. The method according to claim 11 , wherein the SARS-CoV-2 variant comprises B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta) or B.1.1.529 (Omicron).
13. The method according to claim 12 , wherein the first agent comprises two or more peptides selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 9.
14. The method according to claim 11 , further comprising administering a second agent.
15. The method according to claim 11 , wherein the first agent is delivered nasally or by inhalation.
16. The method according to claim 14 , wherein the second agent is delivered systemically.
17. A method of halting the further progression of or worsening of the symptoms associated with COVID-19, the method comprising administering a first agent to a subject in need thereof, the first agent comprising an isolated peptide that inhibits the association between SARS- CoV-2 spike 51 of a SARS-CoV-2 variant and Angiotensin Converting Enzyme-2 (ACE-2) without inhibiting the activity of ACE-2, wherein the first agent comprises an isolated peptide selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 9.
18. The method according to claim 17 , wherein the SARS-CoV-2 variant comprises B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta) or B.1.1.529 (Omicron).
19. The method according to claim 17 , wherein the first agent comprises two or more peptides selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 9.
20. The method according to claim 17 , further comprising administering a second agent.
21. The method according to claim 17 , wherein the first agent is delivered nasally or by inhalation.
22. The method according to claim 20 , wherein the second agent is delivered systemically.